• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有证据表明组织蛋白酶K在自然发生的马骨关节炎中会降解关节软骨。

Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis.

作者信息

Vinardell T, Dejica V, Poole A R, Mort J S, Richard H, Laverty S

机构信息

Département des sciences cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada.

出版信息

Osteoarthritis Cartilage. 2009 Mar;17(3):375-83. doi: 10.1016/j.joca.2008.07.017. Epub 2008 Sep 21.

DOI:10.1016/j.joca.2008.07.017
PMID:18809344
Abstract

OBJECTIVE

The mechanisms leading to degeneration of articular cartilage in osteoarthritis (OA) are complex and not yet fully understood. Cathepsin K (CK) is a cysteine protease which can also cleave the triple helix of type II collagen. This exposes a neoepitope that can now be identified by specific antibodies. The aim of this study was to obtain evidence suggesting a role for CK in naturally occurring equine OA in both lesional and peri-lesional regions.

METHODS

Articular cartilages (n=12 horses; 5 healthy, 7 OA) were harvested from animals postmortem. A gross macroscopic examination, histologic (Safranin O-Fast Green and Picrosirius red staining) and immunohistochemical evaluation were performed. Samples were divided into normal appearing cartilage, peri-lesional and lesional cartilage. Cartilage degradation in the samples was graded histologically and immunohistochemically. CK and possible CK cleavage were detected immunohistochemically with specific anti-protein and anti-neoepitope antibodies, respectively. A comparison of CK neoepitope (C2K) production with the collagenase-generated neoepitope produced by matrix metalloproteinases (MMP)-1, 8 and 13 (C2C) was also assessed immunohistochemically.

RESULTS

CK and CK cleavage were significantly more abundant in OA cartilage (both peri-lesional and lesional) when compared to remote cartilage within the sample joint or cartilage from healthy joints. The immunohistochemical pattern observed for CK degradation (C2K) was similar to that of collagenase degradation (C2C). Macroscopic cartilage changes and histologic findings were significantly correlated with immunohistochemistry results.

CONCLUSION

The data generated suggests that CK may be involved in cartilage collagen degradation in naturally occurring osteoarthritis.

摘要

目的

骨关节炎(OA)中导致关节软骨退变的机制复杂,尚未完全明确。组织蛋白酶K(CK)是一种半胱氨酸蛋白酶,它也能切割Ⅱ型胶原的三股螺旋结构。这会暴露出一个新表位,现在可以通过特异性抗体识别。本研究的目的是获得证据,表明CK在自然发生的马OA的病变区和病变周围区域发挥作用。

方法

从死后的动物身上获取关节软骨(n = 12匹马;5匹健康,7匹OA)。进行大体宏观检查、组织学(番红O-固绿和天狼星红染色)和免疫组织化学评估。样本分为外观正常的软骨、病变周围软骨和病变软骨。对样本中的软骨退变进行组织学和免疫组织化学分级。分别用特异性抗蛋白抗体和抗新表位抗体免疫组织化学检测CK和可能的CK切割情况。还通过免疫组织化学评估了CK新表位(C2K)的产生与基质金属蛋白酶(MMP)-1、8和13产生的胶原酶生成新表位(C2C)的比较。

结果

与样本关节内的远端软骨或健康关节的软骨相比,OA软骨(病变周围和病变区)中的CK和CK切割明显更丰富。观察到的CK降解(C2K)的免疫组织化学模式与胶原酶降解(C2C)相似。宏观软骨变化和组织学结果与免疫组织化学结果显著相关。

结论

所产生的数据表明,CK可能参与自然发生的骨关节炎中软骨胶原的降解。

相似文献

1
Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis.有证据表明组织蛋白酶K在自然发生的马骨关节炎中会降解关节软骨。
Osteoarthritis Cartilage. 2009 Mar;17(3):375-83. doi: 10.1016/j.joca.2008.07.017. Epub 2008 Sep 21.
2
Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage.随着年龄的增长和骨关节炎的发生,人关节软骨中组织蛋白酶 K 和胶原酶活性增加导致 II 型胶原裂解增加。
Arthritis Res Ther. 2012 May 14;14(3):R113. doi: 10.1186/ar3839.
3
Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage.组织蛋白酶K对人骨关节炎软骨中II型胶原蛋白的切割作用
Am J Pathol. 2008 Jul;173(1):161-9. doi: 10.2353/ajpath.2008.070494. Epub 2008 May 29.
4
Comparison of collagenase-cleaved articular cartilage collagen in mice in the naturally occurring STR/ort model of osteoarthritis and in collagen-induced arthritis.
Osteoarthritis Cartilage. 2002 Mar;10(3):172-9. doi: 10.1053/joca.2001.0500.
5
C2K77 ELISA detects cleavage of type II collagen by cathepsin K in equine articular cartilage.C2K77 ELISA 检测组织蛋白酶 K 对马关节软骨中 II 型胶原的裂解。
Osteoarthritis Cartilage. 2017 Dec;25(12):2119-2126. doi: 10.1016/j.joca.2017.08.011. Epub 2017 Sep 4.
6
Use of an antineoepitope antibody for identification of type-II collagen degradation in equine articular cartilage.使用抗新表位抗体鉴定马关节软骨中II型胶原蛋白的降解情况。
Am J Vet Res. 2001 Jul;62(7):1031-9. doi: 10.2460/ajvr.2001.62.1031.
7
Early cathepsin K degradation of type II collagen in vitro and in vivo in articular cartilage.体外和体内关节软骨中 II 型胶原的早期组织蛋白酶 K 降解。
Osteoarthritis Cartilage. 2016 Aug;24(8):1461-9. doi: 10.1016/j.joca.2016.03.016. Epub 2016 Apr 2.
8
Chondrocyte death by apoptosis is associated with the initiation and severity of articular cartilage degradation.软骨细胞凋亡性死亡与关节软骨降解的发生和严重程度有关。
Int J Rheum Dis. 2011 May;14(2):191-8. doi: 10.1111/j.1756-185X.2010.01578.x. Epub 2010 Oct 26.
9
Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13.衰老和骨关节炎关节软骨中II型胶原蛋白的胶原酶切割位点及变性情况及其与基质金属蛋白酶1和基质金属蛋白酶13分布的关系
Arthritis Rheum. 2002 Aug;46(8):2087-94. doi: 10.1002/art.10428.
10
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation.基质金属蛋白酶和半胱氨酸蛋白酶活性对细胞因子刺激的关节软骨降解的相对贡献。
Osteoarthritis Cartilage. 2006 Aug;14(8):738-48. doi: 10.1016/j.joca.2006.01.016. Epub 2006 Mar 23.

引用本文的文献

1
Cathepsin K Inhibitors as Potential Drugs for the Treatment of Osteoarthritis.组织蛋白酶K抑制剂作为治疗骨关节炎的潜在药物
Int J Mol Sci. 2025 Mar 22;26(7):2896. doi: 10.3390/ijms26072896.
2
Assessment of the circulatory concentrations of cathepsin D, cathepsin K, and alpha-1 antitrypsin in patients with knee osteoarthritis.评估膝关节骨关节炎患者组织蛋白酶 D、组织蛋白酶 K 和α1-抗胰蛋白酶的循环浓度。
Ir J Med Sci. 2023 Jun;192(3):1191-1196. doi: 10.1007/s11845-022-03061-3. Epub 2022 Jun 24.
3
The Bone Cartilage Interface and Osteoarthritis.
骨软骨界面与骨关节炎。
Calcif Tissue Int. 2021 Sep;109(3):303-328. doi: 10.1007/s00223-021-00866-9. Epub 2021 Jun 4.
4
Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain.组织蛋白酶K抑制剂L-006235在碘乙酸钠骨关节炎疼痛模型中的镇痛作用。
Pain Rep. 2018 Oct 5;3(6):e685. doi: 10.1097/PR9.0000000000000685. eCollection 2018 Nov.
5
Cathepsin K Localizes to Equine Bone and Inhibits Bone Marrow Stem and Progenitor Cells Differentiation .组织蛋白酶K定位于马骨并抑制骨髓干细胞和祖细胞分化。
J Stem Cells Regen Med. 2017 Dec 18;13(2):45-53. doi: 10.46582/jsrm.1302008. eCollection 2017.
6
Overexpression of cystatin C in synovium does not reduce synovitis or cartilage degradation in established osteoarthritis.在已确诊的骨关节炎中,滑膜中胱抑素C的过表达并不能减轻滑膜炎或软骨降解。
Arthritis Res Ther. 2015 Jan 16;17(1):5. doi: 10.1186/s13075-015-0519-3.
7
Cordycepin modulates inflammatory and catabolic gene expression in interleukin-1beta-induced human chondrocytes from advanced-stage osteoarthritis: an in vitro study.虫草素对晚期骨关节炎患者白细胞介素-1β诱导的人软骨细胞中炎症和分解代谢基因表达的调节作用:一项体外研究。
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6575-84. eCollection 2014.
8
Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage.随着年龄的增长和骨关节炎的发生,人关节软骨中组织蛋白酶 K 和胶原酶活性增加导致 II 型胶原裂解增加。
Arthritis Res Ther. 2012 May 14;14(3):R113. doi: 10.1186/ar3839.
9
Carrageenan-induced transient inflammation in a rabbit knee model: molecular changes consistent with an early osteoarthritis phenotype.卡拉胶诱导兔膝关节模型中的短暂炎症:与早期骨关节炎表型一致的分子变化。
Inflamm Res. 2012 Aug;61(8):907-14. doi: 10.1007/s00011-012-0483-1. Epub 2012 May 13.
10
Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.基质金属蛋白酶13缺陷型小鼠对骨关节炎软骨侵蚀具有抗性,但对软骨细胞肥大或骨赘形成没有抗性。
Arthritis Rheum. 2009 Dec;60(12):3723-33. doi: 10.1002/art.25002.